AIM ImmunoTech Inc.
AIM ImmunoTech completed final dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with topline data expected in Q1 2027. The company also reported encouraging findings from a Netherlands Named Patient Program.
AIM ImmunoTech Inc. (AIM) highlighted Ampligen's potential in pancreatic cancer treatment following FDA approval of Revolution Medicines' daraxonrasib. CEO Thomas Equels outlined Ampligen's differentiated mechanism and clinical potential, citing median overall survival of 34.8 months in a selected patient population versus 12.5 months in historical controls.
Equels Thomas K (CEO & President) purchased 24,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-17.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AIM (AIM ImmunoTech Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AIM coverage spans insider activity, corporate actions and financial news.
In the last 30 days, AIM insiders filed 4 SEC Form 4 transactions — 4 purchases ($13K) and no sales. The most active reporter was Equels Thomas K, CEO & President, with 4 filings.
The dosing completion is a catalyst that could drive the stock higher if the upcoming data are positive.
Positive clinical signals could boost investor sentiment and drive short‑term price appreciation if data are validated.
Small insider buy signals modest confidence but limited price impact.
Insider purchase signals confidence and may support short-term price upside.
Minor insider purchase signals confidence but is too small to move price.
AlphAI scores every news story that mentions AIM with an AI model for sentiment and relevance, and aggregates insider trades from AIM ImmunoTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AIM ImmunoTech completed final dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with topline data expected in Q1 2027. The company also reported encouraging findings from a Netherlands Named Patient Program.
1 min readAIM ImmunoTech Inc. (AIM) highlighted Ampligen's potential in pancreatic cancer treatment following FDA approval of Revolution Medicines' daraxonrasib. CEO Thomas Equels outlined Ampligen's differentiated mechanism and clinical potential, citing median overall survival of 34.8 months in a selected patient population versus 12.5 months in historical controls.
2 min readEquels Thomas K (CEO & President) purchased 24,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-17.
1 min readEquels Thomas K (CEO & President) purchased 11,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-16.
1 min readEquels Thomas K (CEO & President) purchased 22,000 shares of AIM ImmunoTech Inc. (AIM) at $0.22 on 2026-09-15.
1 min readEquels Thomas K (CEO & President) purchased 5,900 shares of AIM ImmunoTech Inc. (AIM) at $0.22 on 2026-09-14.
1 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. From September 8, 2026 to September 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together,
1 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together,
1 min readAIM ImmunoTech (AIM) is advancing Ampligen in a Phase 2 study for pancreatic cancer, combining it with AstraZeneca's durvalumab. The DURIPANC study aims to assess its effectiveness as maintenance therapy. AIM believes Ampligen could enhance immune responses and improve treatment outcomes. The company expects data soon and plans further regulatory discussions. AIM's stock is currently trading at $0.23, up 1.94%.
1 min readAIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of five exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (togethe
2 min read
